Matches in Nanopublications for { ?s ?p "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP469094.RASoQE4Rn7qKLlbXQrexx7bj7RpHOAzfa7K4nNEs3Ki5w130_assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP469094.RASoQE4Rn7qKLlbXQrexx7bj7RpHOAzfa7K4nNEs3Ki5w130_provenance.
- assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP829854.RAZE_8_c2ltfTlSDMZJ38lyQ2Df5CfutcT6TYat17wZY0130_assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829854.RAZE_8_c2ltfTlSDMZJ38lyQ2Df5CfutcT6TYat17wZY0130_provenance.
- NP845584.RAPINy9N9AtcvBwFMSwunwuL_-zVhdh04u0xHmz9pSEdk130_assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP845584.RAPINy9N9AtcvBwFMSwunwuL_-zVhdh04u0xHmz9pSEdk130_provenance.
- NP829855.RAht3-DL5fq_Lv5kVtezeX4JhkgVWsGAzNL60AhsFbJ_E130_assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829855.RAht3-DL5fq_Lv5kVtezeX4JhkgVWsGAzNL60AhsFbJ_E130_provenance.
- NP829853.RA7kR_vE_dChv2a-CNxt9IU-FxJbE-5GU7Jw9sRRy_35E130_assertion description "[Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829853.RA7kR_vE_dChv2a-CNxt9IU-FxJbE-5GU7Jw9sRRy_35E130_provenance.